1. Home
  2. GVH vs SILO Comparison

GVH vs SILO Comparison

Compare GVH & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globavend Holdings Limited

GVH

Globavend Holdings Limited

N/A

Current Price

$0.92

Market Cap

2.6M

Sector

N/A

ML Signal

N/A

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

N/A

Current Price

$1.23

Market Cap

3.1M

ML Signal

N/A

Company Overview

Basic Information
Metric
GVH
SILO
Founded
2016
2010
Country
Australia
United States
Employees
N/A
N/A
Industry
Apparel
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
3.1M
IPO Year
2023
2011

Fundamental Metrics

Financial Performance
Metric
GVH
SILO
Price
$0.92
$1.23
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
24.8K
★ 30.0K
Earning Date
07-14-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.98
EPS
★ N/A
N/A
Revenue
N/A
★ $72,102.00
Revenue This Year
$1.85
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.74
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$1.10
52 Week High
$6.46
$10.43

Technical Indicators

Market Signals
Indicator
GVH
SILO
Relative Strength Index (RSI) 43.57 34.34
Support Level $0.87 $1.10
Resistance Level $1.13 $4.80
Average True Range (ATR) 0.07 0.09
MACD 0.00 0.05
Stochastic Oscillator 46.95 39.39

Price Performance

Historical Comparison
GVH
SILO

About GVH Globavend Holdings Limited

Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Share on Social Networks: